Generated record revenue of $23.3 million for the first quarter of 2022
First patient dosed in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.